CoChat

COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm

Open access
Talukdar, Jayanta, Dasgupta, Santanu, Nagle, Vinod, Bhadra, Bhaskar · 2020 · SSRN Electronic Journal
Cited by 57

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The pandemic outbreak of Coronavirus disease (COVID-2019) is a potentially fatal and highly contagious disease. Given that in absence of definitive COVID-19 treatment, and the presence of asymptomatic carriers, the conventional intervention measures to curb the rate of infection and deaths will be highly challenging. Accumulating evidences suggest that excessive reactive inflammation, oxidation, and an exaggerated immune response very likely to contribute to its pathology, leads by a violent immune response cytokine storm and subsequent progression to life threatening acute respiratory distress syndrome (ARDS)/acute lung injury (ALI). Microalgae derived natural astaxanthin (nASX), a well-known potent anti-oxidant and broad-spectrum anti-inflammatory compound with impressive safety profile, is protective against cytokine storm, ALI/ARDS. This article summarizes the most likely benefits of nASX may provide as an adjunctive in attenuation of COVID-19 induced health adversaries based on its putative pathogenesis. There is rationale, pre-clinical evidences of effectiveness and evidence of safety from long-time use for other indications to justify possible inclusion of nASX as adjunctive in combination with primary anti-viral drugs therapy will hugely benefit COVID-19 patients by improving their health and reducing recovery time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2139/ssrn.3579738

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 67

  1. P Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 10.1038/s41586-020-2012-7 · DOI · Paper page
  2. C Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 30183, 10.1016/S0140-6736(20 · doi:10.1016/s0140-6736(20
  3. C K Wong, 2004, Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome, Clin Exp Immunol, 136, 95, 10.1111/j.1365-2249.2004.02415.x · DOI · Paper page
  4. Y Chen, 2020, Emerging coronaviruses: Genome structure, replication, and pathogenesis, J Med Virol, 92, 418, 10.1002/jmv.25681 · DOI · Paper page
  5. P Kidd, 2011, cell membrane nutrient with diverse clinical benefits and anti-aging potential, Altern. Med. Rev, 16, 355
  6. J Dhinaut, 2017, A dietary carotenoid reduces immunopathology and ehances longevity through an immune depressive effect in an insect model, Scientific Rep, 10.1038/s41598-017-12769-7 · DOI
  7. X Cai, 2019, Astaxanthin prevents against lipopolysaccharide-induced acute lung injury and sepsis via inhibiting activation of MAPK/NF-?B, Am J Transl Res, 11
  8. X Li, 2020, Molecular immune pathogenesis and diagnosis of COVID-19, Journal of Pharmaceutical Analysis, 10.1016/j.jpha.2020.03.001 · DOI · Paper page
  9. D Wang, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, JAMA, 10.1001/jama.2020.1585 · DOI · Paper page
  10. Z Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine, 10.1016/s2213-2600(20)30076-x · DOI · Paper page
  11. W J Guan, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine, 10.1056/NEJMoa2002032 · DOI · Paper page
  12. A E Williams, 2014, The mercurial nature of neutrophils: still an enigma in ARDS?, Am. J. Physiol. Lung Cell Mol. Physiol, 10.1152/ajplung.00311.2013 · DOI · Paper page
  13. Y Shi, 2020, COVID-19 infection: the perspectives on immune responses, Cell Death & Differ, 10.1038/s41418-020-0530-3 · DOI · Paper page
  14. Y Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci. China Life Sci, 63, 364, 10.1007/s11427-020-1643-8 · DOI · Paper page
  15. R O Bonow, 2020, Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality, JAMA Cardiol, 10.1001/jamacardio.2020.1105 · DOI · Paper page
  16. N Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/s0140-6736(20)30211-7 · DOI · Paper page
  17. K W Chan, COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese -Western medicine for the management of 2019 novel coronavirus disease, 10.1142/s0192415x20500378 · DOI · Paper page
  18. F Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, 30566, 10.1016/S0140-6736(20 · doi:10.1016/s0140-6736(20
  19. G Maclaren, 2020, Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation, JAMA, 10.1001/jama.2020.2342 · DOI · Paper page
  20. R Channappanavar, 2016, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe, 10.1016/j.chom.2016.01.007 · DOI · Paper page
  21. R Channappanavar, IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes, J. Clin. Invest, 10.1172/jci126363 · DOI · Paper page
  22. R Channappanavar, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol, 10.1007/s00281-017-0629-x · DOI · Paper page
  23. 10.1007/s00281-017-0629-x · DOI · Paper page
  24. H Lu, 2020, Drug treatment options for the 2019-new coronavirus (2019-nCoV), Biosci. Trends, 10.5582/bst.2020.01020 · DOI · Paper page
  25. Y M Arabi, Treatment of Middle East respiratory syndrome with a combination of lopinavir/ ritonavir and interferon-?1b (MIRACLE trial): statistical analysis plan for a recursive two stage group sequential randomized controlled trial, 10.1186/s13063-019-3846-x · DOI · Paper page
  26. J Gao, 2020, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, 14, 10.5582/bst.2020.01047 · DOI · Paper page
  27. M Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 10.1038/s41422-020-0282-0 · DOI · Paper page
  28. K Zhang, 2020, Is traditional Chinese medicine useful in the treatment of COVID-19?, Am J Emerg Med, 10.1016/j.ajem.2020.03.046 · doi:10.1016/j.ajem.2020.03.046
  29. J T Poston, 2020, Management of critically ill adults with COVID-19, JAMA. Crit Care Med
  30. R Zhang, 2020, COVID-19: Melatonin as a potential adjuvant treatment, Life Sciences, 10.1016/j.lfs.2020.117583 · DOI · Paper page
  31. R R Ambati, 2014, Astaxanthin: Source, Extraction, Stability, Biological activities and Its commercial applications -a review, Mar. Drugs, 10.3390/md12010128 · DOI · Paper page
  32. F J Pashkow, 2008, Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease, Am. J. Cardiol, 101, 58, 10.1016/j.amjcard.2008.02.010 · DOI · Paper page
  33. M P Barros, Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil, Nutrients, 2014, 1293, 10.3390/nu6031293 · DOI
  34. B P Chew, The immune system and disease, Carotenoids: Nutrition and Health
  35. J S Park, 2010, Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans, Nutr. Metab, 7, 18, 10.1186/1743-7075-7-18 · DOI · Paper page
  36. G N Coral-Hinostroza, 2004, Plasma appearance of unesterified astaxantin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters, Comp Biochem Physiol C Toxicol Pharmacol, 139, 99, 10.1016/j.cca.2004.09.011 · DOI
  37. B Capelli, 2019, Astaxanthin sources: suitability for human health and nutrition, Functional Foods in Health and Disease, 9, 10.31989/ffhd.v9i6.584 · DOI · Paper page
  38. E G Rosenbaugh, 2013, Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases, Am J Physiol Regul Integr Comp Physiol, 10.1152/ajpregu.00395.2012 · DOI
  39. M Sztretye, 2019, Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging, Oxidative Medicine and Cellular Longevity, 10.1155/2019/3849692 · DOI · Paper page
  40. H Cui, 2012, Oxidative stress, mitochondrial dysfunction, and aging, Journal of Signal Transduction, 10.1155/2012/646354 · DOI · Paper page
  41. R Hoffman, Astaxanthin extends lifespan via altered biogenesis of the mitochondrial respiratory chain complex III, 10.1101/698001 · DOI
  42. H Wu, 2015, Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases, 5750, 10.3390/md13095750 · DOI · Paper page
  43. Y Nishida, 2007, Quenching activities of common hydrophilic and lipophilic antioxidants against singlet oxygen using chemiluminescence detection system, Carotenoid Science, 11, 16
  44. X Zhang, 2018, Astaxanthin mitigates subarachnoid hemorrhage injury primarily by increasing sirtuin 1 and inhibiting the Toll-like receptor 4 signaling pathway, 10.1096/fj.201800642rr · DOI
  45. M Miyachi, 2015, Anti-inflammatory effects of astaxanthin in the human gingival keratinocyte line NDUSD1
  46. S J Lee, 2003, Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinasedependent NF-kappaB activation, Mol Cells, 16, 97, 10.1016/S1016-8478(23)13772-1 · DOI · Paper page
  47. K C Chan, 2012, Anticoagulatory and anti-inflammatory effects of astaxanthin in diabetic rats, J Food Sci, 77, 76, 10.1111/j.1750-3841.2011.02558.x · DOI
  48. M Yamamoto, 2010, Lipid A receptor TLR4-mediated signaling pathways, Adv Exp Med Biol, 667, 59
  49. J C Merrill, 2011, Whole-body deletion of LPS-induced TNFalpha factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis, Proc Natl Acad Sci U S A, 108, 21247, 10.1073/pnas.1111492108 · doi:10.1073/pnas.1111492108
  50. Z W Zhang, 2016, Mitochondrion-Permeable Antioxidants to Treat ROS-BurstMediated Acute Diseases, 10.1155/2016/6859523 · DOI · Paper page
  51. Lin, 2016, Stimulates Immune Responses by Enhancing IFN-and IL-2 Secretion in Primary Cultured Lymphocytes in Vitro and ex Vivo, 10.3390/ijms17010044 · DOI
  52. D Gao, 2019, Astaxanthin attenuate iohexol-induced human proximal renal tubular epithelial cells injury via the ROS/NLRP3 inflammasome signal pathway, SDRP Journal of Food Science & Technology, 4, 10.25177/jfst.4.3.ra.503 · doi:10.25177/jfst.4.3.ra.503
  53. S Fakhri, 2019, The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective, Molecules, 24, 10.3390/molecules24142640 · DOI · Paper page
  54. X Song, 2014, Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signaling pathway, J. Cell. Mol. Med, 18, 2198, 10.1111/jcmm.12347 · DOI
  55. 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, 10.1016/S0140-6736(20)30317-2 · DOI · Paper page
  56. M A Matthay, 2020, Treatment of severe acute respiratory syndrome from COVID-19, The Lancet, 30121, 10.1016/S2213-2600 · doi:10.1016/s2213-2600
  57. A S Abdulamir, 2020, The possible immunological pathway for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children, Electron J Gen Med, 17, 10.29333/ejgm/7850 · DOI · Paper page
  58. J S Park, 2010, Astaxanthin uptake in domestic dogs and cats, Nutrition & Metabolism, 7, 10.1186/1743-7075-7-52 · DOI
  59. B P Chew, 1999, Dietary b-carotene and astaxanthin but not canthaxanthin stimulate splenocyte function in mice, Anticancer Re, 19, 5223
  60. M Bennedsen, 1999, Treatment of H. pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes, Immunol Lett, 70, 185, 10.1016/s0165-2478(99)00145-5 · DOI · Paper page
  61. Acm Boon, 2002, Invitro effect of bioactive compounds on Influenza Virus specific B-and T-cell responses, Scan J Immunology, 55, 24, 10.1046/j.1365-3083.2002.01014.x · DOI
  62. Sal Sep�lveda, 2019, Antioxidants benefits in hepatitis C infection in the new DAAs era, Annals of Hepatology, 18, 410, 10.1016/j.aohep.2019.04.004 · doi:10.1016/j.aohep.2019.04.004
  63. M Wang, 2013, Astaxanthin ameliorates lung fibrosis in vivo and in vitro by preventing transdifferentiation, inhibiting proliferation and promoting apoptosis of activated cells, Food and Chem. Toxicol, 450, 10.1016/j.fct.2013.03.004 · DOI
  64. W Xu, Astaxanthin protects OTA-induced lung injury in mice through Nrf2/NF-kB pathway, Toxins, 2019, 10.3390/toxins11090540 · DOI
  65. W Diao, 2019, Astaxanthin protects against renal fibrosis through inhibiting myofibroblast activation and promoting CD8 + T cell recruitment, 10.1016/j.bbagen.2019.05.020 · DOI
  66. R G Fassett, 2011, Astaxanthin: A potential therapeutic agent in cardiovascular disease, 9, 447, 10.3390/md9030447 · DOI · Paper page
  67. H Hashimoto, 2019, Effects of astaxanthin on VEGF level and antioxidation in human aqueous humor: difference by sex, 10.3164/jcbn.18-110 · doi:10.3164/jcbn.18-110

Cited by

See all 57

Metadata

Authors
Talukdar, J., Dasgupta, S., Nagle, V., & Bhadra, B.
Venue
SSRN Electronic Journal
Publisher
Elsevier BV
Published
2020
ISSN
1556-5068 (ISSN-L)
OpenAlex
W3021868697
Cited by
57
References
5
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm. https://app.cochat.ai/papers/10.2139/ssrn.3579738
The paper
Talukdar, J., Dasgupta, S., Nagle, V., & Bhadra, B. (2020). COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3579738

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.